Essais liés8clinical trials
VillePhoenixlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06455449

Ouvrir le site du centre

Essais cliniques associés

8
MoléculeIndication / populationPhaseNCTTitreStatut
Anifrolumab Myopathies Phase 3 NCT07691970 ROSY-S — Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment RECRUITING
Anifrolumab (blinded) Myopathies Phase 3 NCT06455449 JASMINE — A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) RECRUITING
Ivonescimab Dose 1 Cancer Phase 2/3 NCT07815665 HARMONi-GU1 — A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma RECRUITING
Anifrolumab Lupus Phase 3 NCT07430306 SUNFLOWER — A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus RECRUITING
Rilvegostomig Cancer Phase 3 NCT06627647 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC RECRUITING
Anifrolumab Lupus Phase 3 NCT05835310 BLOSSOM — An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants RECRUITING
natalizumab SEP Phase 1 NCT00559702 Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) COMPLETED
Medi-546 Lupus Phase 3 NCT04877691 Tulip SC — Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus ACTIVE_NOT_RECRUITING